Vaxcyte Stock Soars After Pneumonia Vaccine Meets Late-Stage Trial Goals
Vaxcyte (PCVX) shares jumped over 60% as its experimental pneumococcal vaccine successfully met the primary endpoints in a pivotal late-stage trial for adult use. This success positions the biotech to compete with established players like Pfizer and Merck in the multibillion-dollar vaccine market.